Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 4/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.40 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1321696 | 0.86 | ABL1 (0.43) | ABL1LRRK2CYP11B1CYP11B2GABRA1 | |
| SCHEMBL2356036 | 0.85 | ABL1 (0.42) | ABL1LRRK2CYP11B1CYP11B2GABRA1 | |
| SCHEMBL2356032 | 0.85 | ABL1 (0.42) | ABL1LRRK2CYP11B1CYP11B2GABRA1 | |
| SCHEMBL1319379 | 0.83 | CSNK1D (0.42) | ABL1LRRK2CYP11B1CYP11B2GABRA1 | |
| SCHEMBL1321828 | 0.83 | KCNQ2 (0.43) | ABL1LRRK2CYP11B1CYP11B2GABRA1 | |
| SCHEMBL1320171 | 0.83 | NPC1 (0.49) | GABRA1GABRB2KDM4EALDH1A1RAB9A | |
| SCHEMBL15631803 | 0.83 | CYP11B1 (0.44) | ABL1LRRK2CYP11B1CYP11B2GABRA1 | |
| SCHEMBL9893317 | 0.82 | ALDH1A1 (0.51) | ABL1LRRK2GABRB2KDM4EALDH1A1 | |
| SCHEMBL9893344 | 0.81 | MCHR1 (0.46) | ABL1LRRK2KDM4EALDH1A1MCHR1 | |
| SCHEMBL1319308 | 0.80 | ABL1 (0.41) | ABL1LRRK2CYP11B1CYP11B2GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9067935-B2 | Imidazo[1,2-α]pyridine sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2015-06-30 | — | — | US | disclosed |
| US-20140088098-A1 | IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2014-03-27 | — | — | US | disclosed |
| US-8618150-B2 | Imidazo[1,2-α]pyridine sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2013-12-31 | — | — | US | disclosed |
| EP-2649072-A1 | IMIDAZO [1, 2-A]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2013-10-16 | — | — | EP | disclosed |
| US-20120149699-A1 | IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2012-06-14 | — | — | US | disclosed |
| WO-2012078994-A1 | IMIDAZO [1, 2-A] PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149699-A1 | IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS | TRPM8, TRPV1, TRPM2 | ABL1 1348/4885LRRK2 1493/4885CYP11B1 3773/4885 |
| US-20140088098-A1 | IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS | TRPM8, TRPV1, TRPM2 | ABL1 1348/4885LRRK2 1493/4885CYP11B1 3773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.